XML 36 R22.htm IDEA: XBRL DOCUMENT v3.3.0.814
Marketable Securities and Fair Value Measurements (Tables)
9 Months Ended
Sep. 30, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Financial assets and liabilities measured at fair value on a recurring basis
The following table presents the Company’s assets and liabilities that are measured at fair value on a recurring basis, and are determined using the following inputs as of September 30, 2015:
 
 
Fair Value Measurements at
 
September 30, 2015
 
Total
 
Quoted Prices
in Active Markets
(Level 1)
 
Significant
Other Unobservable
Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
Assets:
 
 
 
 
 
 
 
Money market funds
$
53,090,572

 
$
53,090,572

 
$

 
$

Mutual funds
58,235,334

 

 
58,235,334

 

US corporate debt securities
26,975,079

 

 
26,975,079

 

Municipal bonds
103,143

 

 
103,143

 

Investments in affiliated entities
25,321,361

 
25,321,361

 

 

Common stock warrants
88,900

 

 

 
88,900

Total Assets
$
163,814,389

 
$
78,411,933

 
$
85,313,556

 
$
88,900

Liabilities:
 
 
 
 
 
 
 
Common stock warrants
$
1,093,752

 
$

 
$

 
1,093,752

Total Liabilities
$
1,093,752

 
$

 
$

 
$
1,093,752


The following table presents the Company’s assets and liabilities that are measured at fair value on a recurring basis, and are determined using the following inputs as of December 31, 2014:
 
 
Fair Value Measurements at
 
December 31, 2014
 
Total
 
Quoted Prices
in Active Markets
(Level 1)
 
Significant
Other Unobservable
Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
Assets:
 
 
 
 
 
 
 
Money market funds
$
36,474,066

 
$
36,474,066

 
$

 
$

Mutual funds
29,273,635

 

 
29,273,635

 

US corporate debt securities
23,802,339

 

 
23,802,339

 

Investment in affiliated entity
12,340,811

 
12,340,811

 

 

Common stock warrants
550,000

 

 

 
550,000

Total Assets
$
102,440,851

 
$
48,814,877

 
$
53,075,974

 
$
550,000

Liabilities:
 
 
 
 
 
 
 
Common stock warrants
$
2,022,729

 
$

 
$

 
$
2,022,729

Total Liabilities
$
2,022,729

 
$

 
$

 
$
2,022,729

Assumptions used to estimate the fair values of the common stock warrants
The assumptions used to estimate the fair value of common stock warrants at September 30, 2015 are presented below:
 
Risk-free interest rate
0.92%
Expected volatility
83%
Expected life in years
3.0
Dividend yield
Change in fair value of the financial assets
The following table presents a summary of changes in fair value of the Company’s total Level 3 financial assets for the nine months ended September 30, 2015:
Balance at January 1, 2015
$
550,000

Decrease in fair value included in change in fair value of common stock warrants
(461,100
)
Balance at September 30, 2015
$
88,900


Changes in fair value of the financial liabilities
The following table presents the changes in fair value of the Company’s total Level 3 financial liabilities for the nine months ended September 30, 2015:
 
Balance at January 1, 2015
$
2,022,729

Decrease in fair value included in change in fair value of common stock warrants
(928,977
)
Balance at September 30, 2015
$
1,093,752

OncoSec [Member]  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Assumptions used to estimate the fair values of the common stock warrants
The assumptions used to estimate the fair values of the OncoSec common stock warrants at September 30, 2015 are presented below:

Risk-free interest rate
0.33-0.49%
Expected volatility
90%
Expected life in years
1.0-1.5
Dividend yield